Ryan Specialty Holdings, Inc. (RYAN)
| Market Cap | 8.26B -54.7% |
| Revenue (ttm) | 3.10B +19.6% |
| Net Income | 108.69M +115.3% |
| EPS | 0.77 +187.1% |
| Shares Out | 263.66M |
| PE Ratio | 40.41 |
| Forward PE | 14.93 |
| Dividend | $0.52 (1.66%) |
| Ex-Dividend Date | May 12, 2026 |
| Volume | 2,644,281 |
| Open | 31.57 |
| Previous Close | 31.71 |
| Day's Range | 31.02 - 32.09 |
| 52-Week Range | 29.28 - 72.50 |
| Beta | 0.67 |
| Analysts | Buy |
| Price Target | 48.47 (+54.81%) |
| Earnings Date | Apr 30, 2026 |
About RYAN
Ryan Specialty Holdings, Inc. operates as a service provider of specialty products and solutions for insurance brokers, agents, and carriers in the United States, Canada, the United Kingdom, rest of Europe, India, Singapore, and internationally. The company offers distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter or a program administrator with delegated authority from insurance carriers. It serves commercial, industrial, institutional, indivi... [Read more]
Financial Performance
In 2025, Ryan Specialty Holdings's revenue was $2.99 billion, an increase of 21.95% compared to the previous year's $2.46 billion. Earnings were $63.40 million, a decrease of -33.03%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for RYAN stock is "Buy." The 12-month stock price target is $48.47, which is an increase of 54.81% from the latest price.
News
Ryan Specialty price target lowered to $45 from $50 at Morgan Stanley
Morgan Stanley analyst Bob Huang lowered the firm’s price target on Ryan Specialty (RYAN) to $45 from $50 and keeps an Overweight rating on the shares.
Ryan Specialty Holdings, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Ryan Specialty Holdings, Inc. (NYSE: RYAN). The investigation focuses on Ry...
Ryan Specialty price target lowered to $51 from $59 at UBS
UBS analyst Brian Meredith lowered the firm’s price target on Ryan Specialty (RYAN) to $51 from $59 and keeps a Buy rating on the shares.
Ryan Specialty price target lowered to $50 from $55 at Citi
Citi analyst Matthew Heimermann lowered the firm’s price target on Ryan Specialty (RYAN) to $50 from $55 and keeps a Buy rating on the shares.
Ryan Specialty price target lowered to $42 from $49 at Goldman Sachs
Goldman Sachs analyst Robert Cox lowered the firm’s price target on Ryan Specialty (RYAN) to $42 from $49 and keeps a Buy rating on the shares. Investors are expected to
Ryan Specialty price target lowered to $35 from $42 at Mizuho
Mizuho lowered the firm’s price target on Ryan Specialty (RYAN) to $35 from $42 and keeps a Neutral rating on the shares.
Ryan Specialty price target lowered to $42 from $49 at Keefe Bruyette
Keefe Bruyette lowered the firm’s price target on Ryan Specialty (RYAN) to $42 from $49 and keeps an Outperform rating on the shares.
Ryan Specialty price target lowered to $35 from $43 at Piper Sandler
Piper Sandler lowered the firm’s price target on Ryan Specialty (RYAN) to $35 from $43 and keeps a Neutral rating on the shares. The firm notes the company reported a
Ryan Specialty price target lowered to $39 from $41 at Barclays
Barclays lowered the firm’s price target on Ryan Specialty (RYAN) to $39 from $41 and keeps an Overweight rating on the shares.
Wells downgrades Ryan Specialty to Equal Weight on below peer growth
Wells Fargo downgraded Ryan Specialty (RYAN) to Equal Weight from Overweight with a price target of $31, down from $42, following the fiscal Q2 report. The company lowered its fiscal
Ryan Specialty downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo analyst Elyse Greenspan downgraded Ryan Specialty (RYAN) to Equal Weight from Overweight with a $31 price target
Ryan Specialty reports Q2 adjusted EPS 47c, consensus 43c
Reports Q2 revenue $795.2M, consensus $778.48M. “It was a strong start to 2026 for Ryan Specialty (RYAN) in the face of continued and increasing industry headwinds,” said Patrick Ryan, Founder
Ryan Specialty Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw 15% revenue growth and 20% EPS growth, but full-year guidance was lowered to mid-single-digit organic growth due to property rate declines and increased competition. Margin pressure is expected, but investments in AI, talent, and M&A remain priorities.
Ryan Specialty Reports First Quarter 2026 Results
CHICAGO--(BUSINESS WIRE)--Ryan Specialty Holdings, Inc. (NYSE: RYAN) (“Ryan Specialty” or the “Company”), a leading international specialty insurance firm, today announced results for the first quarte...
Ryan Specialty price target lowered to $68 from $70 at BofA
BofA analyst Joshua Shanker lowered the firm’s price target on Ryan Specialty (RYAN) to $68 from $70 and keeps a Buy rating on the shares. The firm adjusted price target
Ryan Specialty price target lowered to $42 from $44 at Mizuho
Mizuho lowered the firm’s price target on Ryan Specialty (RYAN) to $42 from $44 and keeps a Neutral rating on the shares. The firm adjusted estimates and targets among its
Ryan Specialty price target lowered to $43 from $49 at JPMorgan
JPMorgan lowered the firm’s price target on Ryan Specialty (RYAN) to $43 from $49 and keeps an Underweight rating on the shares. The firm adjusted targets in the property and
Ryan Specialty price target lowered to $40 from $45 at Cantor Fitzgerald
Cantor Fitzgerald lowered the firm’s price target on Ryan Specialty (RYAN) to $40 from $45 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in
Ryan Specialty price target lowered to $59 from $65 at UBS
UBS analyst Brian Meredith lowered the firm’s price target on Ryan Specialty (RYAN) to $59 from $65 and keeps a Buy rating on the shares. The firm adjusted targets as
Ryan Specialty price target lowered to $41 from $45 at Barclays
Barclays lowered the firm’s price target on Ryan Specialty (RYAN) to $41 from $45 and keeps an Overweight rating on the shares. The firm adjusted targets in the insurance group
Ryan Specialty price target lowered to $49 from $55 at Keefe Bruyette
Keefe Bruyette lowered the firm’s price target on Ryan Specialty (RYAN) to $49 from $55 and keeps an Outperform rating on the shares.
Ryan Specialty to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026
CHICAGO--(BUSINESS WIRE)--Ryan Specialty Holdings, Inc. (NYSE: RYAN) (“Ryan Specialty”), a leading international specialty insurance firm, today announced it will release its First Quarter 2026 financ...
Ryan Specialty Holdings Earnings Call Transcript: Q4 2025
Revenue grew 21% to over $3B with 10.1% organic growth and strong M&A. Project Empower aims to drive $80M in annual savings by 2029, while a $300M share repurchase and 8% dividend increase reflect confidence in the outlook. 2026 guidance calls for high single-digit organic growth.
Ryan Specialty Reports Fourth Quarter 2025 Results
CHICAGO--(BUSINESS WIRE)--Ryan Specialty Holdings, Inc. (NYSE: RYAN) (“Ryan Specialty” or the “Company”), a leading international specialty insurance firm, today announced results for the fourth quart...
Ryan Specialty Appoints Stephen Stewart CEO of Ryan Specialty Canada Limited
TORONTO--(BUSINESS WIRE)--Ryan Specialty (NYSE: RYAN), a leading international specialty insurance intermediary, is pleased to announce the appointment of Stephen Stewart, President & CEO of Stewart S...